ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
ETF Series Solutions Trust Range Cancer Therapeutics

ETF Series Solutions Trust Range Cancer Therapeutics (CNCR)

15.82
0.56
(3.67%)
At close: July 26 4:00PM
15.82
0.00
( 0.00% )
After Hours: 6:41PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
15.82
Bid
11.88
Ask
17.69
Volume
3,876
15.5377 Day's Range 15.9075
9.22 52 Week Range 18.00
Market Cap
Previous Close
15.26
Open
15.56
Last Trade
2
@
15.76
Last Trade Time
16:50:34
Financial Volume
$ 60,695
VWAP
15.6593
Average Volume (3m)
7,732
Shares Outstanding
800,000
Dividend Yield
-
PE Ratio
-2.72
Earnings Per Share (EPS)
-5.77
Revenue
70k
Net Profit
-4.62M

About ETF Series Solutions Trust Range Cancer Therapeutics

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic f... The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified. Show more

Sector
Mgmt Invt Offices, Open-end
Industry
Mgmt Invt Offices, Open-end
Headquarters
Milwaukee, Wisconsin, USA
Founded
1970
ETF Series Solutions Trust Range Cancer Therapeutics is listed in the Mgmt Invt Offices, Open-end sector of the NASDAQ with ticker CNCR. The last closing price for ETF Series Solutions Tru... was $15.26. Over the last year, ETF Series Solutions Tru... shares have traded in a share price range of $ 9.22 to $ 18.00.

ETF Series Solutions Tru... currently has 800,000 shares outstanding. The market capitalization of ETF Series Solutions Tru... is $12.21 million. ETF Series Solutions Tru... has a price to earnings ratio (PE ratio) of -2.72.

CNCR Latest News

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION PR Newswire OKLAHOMA CITY, Oct. 23, 2023 OKLAHOMA CITY, Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.976.5319865319914.8515.907514.51301815.11702982SP
42.1715.897435897413.6515.9913.0013921513.90338834SP
12-0.08-0.50314465408815.915.9913.0013773214.14078768SP
261.8213141813.00132373815.87293599SP
523.0724.078431372512.75189.221379015.33747586SP
156-14.39-47.633234028530.2131.79.22920216.41124402SP
260-5.03-24.124700239820.8535.8189.22997520.52032757SP

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CGTXCognition Therapeutics Inc
$ 3.44
(45.15%)
4.65M
NAMSNewAmsterdam Pharma Company NV
$ 22.49
(19.25%)
18.82k
RNAZTransCode Therapeutics Inc
$ 0.3474
(17.52%)
6.63M
YYGHYY Group Holding Ltd
$ 0.84
(14.60%)
743
YIBOPlanet Image International Ltd
$ 3.32
(13.89%)
56.87k
VTVTvTv Therapeutics Inc
$ 13.0022
(-38.67%)
33.34k
CEROCERo Therapeutics Holdings Inc
$ 0.1661
(-35.12%)
3.54M
TGLTreasure Global Inc
$ 1.40
(-24.32%)
54.54k
LUXHLuxUrban Hotels Inc
$ 0.1587
(-16.91%)
1.31M
JCSEJE Cleantech Holdings Limited
$ 1.1001
(-12.69%)
681
SLNASelina Hospitality PLC
$ 0.0276
(-8.00%)
24.54M
RNAZTransCode Therapeutics Inc
$ 0.3474
(17.52%)
6.63M
CGTXCognition Therapeutics Inc
$ 3.44
(45.15%)
4.65M
TLTiShares 20 plus Year Treasury Bond
$ 92.90
(-0.10%)
3.91M
CEROCERo Therapeutics Holdings Inc
$ 0.1661
(-35.12%)
3.54M

CNCR Discussion

View Posts
ShadowVolcano37 ShadowVolcano37 3 months ago
Yeah I hear you regarding the new immunotherapy options. I think it's becoming real, although still very expensive.
👍️0
ShadowVolcano37 ShadowVolcano37 3 months ago
Research offers exciting prospects for improving immunotherapy's effectiveness against cancer
https://www.msn.com/en-us/news/other/immunotherapy-a-beacon-of-hope-in-cancer-treatment/
👍️0
ShadowVolcano37 ShadowVolcano37 3 months ago
Cancer Immunotherapy is such an interesting field. I hope it will continue to grow!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
https://twitter.com/bradloncar
👍️0
chmcnfunds chmcnfunds 6 years ago
In @ $24.05. Maybe too early, but near 9 month low:



CNCR
👍️0
chmcnfunds chmcnfunds 6 years ago
Latest Loncar positions and weighs:

http://www.loncarindex.com/cancer-immunotherapy-index-weights


CNCR
👍️0
chmcnfunds chmcnfunds 7 years ago
Loncar blog has increasingly useful data sets:

http://www.loncarblog.com/
👍️0
chmcnfunds chmcnfunds 8 years ago
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Two New Immunotherapy Companies Added to the Index

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and discovering new ways to use the body’s immune system to fight cancer.

The index committee has added BeiGene (Nasdaq: BGNE) and Compugen (Nasdaq: CGEN) to the index.

These additions replace Celyad (Nasdaq: CYAD) and Immune Design (Nasdaq: IMDZ).

“Transformative drug development is happening all over the world,” said Brad Loncar, Chairman of the index committee. “We are pleased to welcome our first components to the index from China and Israel and look forward to following their contributions to the field of cancer immunotherapy.”

The index committee has further decided to institute a minimum equity liquidity threshold of 50,000 shares or $500,000 in average daily trading volume for any index component going forward.

Effective this week, all index holdings have been rebalanced to hold equal weight. The index is rebalanced and reconstituted semi-annually. The next rebalance will occur on December 20, 2016.

Loncar Investments is a proud partner of the Cancer Research Institute, the world’s only nonprofit organization dedicated exclusively to harnessing the immune system’s power to conquer all cancers. To learn about how to give to CRI, please visit here.

Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease. Some immunotherapies have already exhibited uncommon results in clinical trials including partial and complete responses in late stage cancer patients.

About the index: The Loncar Cancer Immunotherapy Index is an equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. This is a sector index similar to Technology sector indices (Internet, Cyber Security, Cloud Computing, etc.). Sector indices allow investors to track interest areas more precisely than broad indices. Additional info can be found at the index’s dedicated website, www.LoncarIndex.com.

Index provider: Loncar Investments LLC was founded by independent biotech investor and analyst Brad Loncar. Mr. Loncar regularly provides his distinctive insight and analysis on this market segment to the investment community via a variety of publishing platforms. Through Loncar Investments LLC, Mr. Loncar has incorporated his extensive research into biotech companies and technologies into developing an index focused on precise investment opportunities. He previously worked in the financial services industry at Franklin Templeton Investments, and was appointed to serve in a Senior Adviser role at the U.S. Department of the Treasury. Mr. Loncar can be followed on Twitter at @bradloncar.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160622005067/en/

Leah Katsanis for ISE ETF Ventures
610-228-2117
ise@gregoryfca.com
👍️0
chmcnfunds chmcnfunds 8 years ago
Brad Loncar tweets:

https://twitter.com/bradloncar

CNCR
👍️0
chmcnfunds chmcnfunds 8 years ago
Current Loncar holdings:

http://www.loncarfunds.com/holdings.aspx

CNCR
👍️0